TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an update.
Xspray Pharma AB has announced a one-day delay in the trading of subscription rights and paid subscribed shares (BTAs) related to its ongoing rights issue, now set to begin on August 27, 2025. This adjustment in the timetable is part of the company’s strategic financial maneuvers to strengthen its market position and support its ambitious product development goals, potentially impacting stakeholders and investors interested in the company’s growth trajectory.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors (PKIs) using its patented HyNap™ technology platform. The company aims to lead the market in enhanced PKIs for cancer treatment, with its lead drug candidate, Dasynoc®, currently under FDA review. Xspray Pharma is expanding its product portfolio with optimized versions of existing cancer drugs.
Average Trading Volume: 40,209
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.64B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.